Gene expression profiling in multiple sclerosis brain

Neurobiology of Disease

Volumn 45, Issue 1, 2012, Pages 108-114

  Dutta, Ranjan ^a   Trapp, Bruce D ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Microarray; Multiple sclerosis; Myelin

Indexed keywords

BETA INTERFERON;

BRAIN; BRAIN TISSUE; CELL INFILTRATION; DEMYELINATION; DOWN REGULATION; GENE EXPRESSION PROFILING; GENE MUTATION; GRAY MATTER; HUMAN; IMMUNE RESPONSE; MICROARRAY ANALYSIS; MOLECULAR PATHOLOGY; MULTIPLE SCLEROSIS; NERVOUS SYSTEM INFLAMMATION; NEUROPATHOLOGY; PRIORITY JOURNAL; REVIEW; WHITE MATTER;

BRAIN; DISEASE PROGRESSION; GENE EXPRESSION PROFILING; HUMANS; MULTIPLE SCLEROSIS;

EID: 81955168154     PISSN: 09699961     EISSN: 1095953X     Source Type: Journal    
DOI: 10.1016/j.nbd.2010.12.003     Document Type: Review

References (84)

1. Achiron A., Gurevich M., Friedman N., Kaminski N., Mandel M. Blood transcriptional signatures of multiple sclerosis: unique gene expression of disease activity. Ann. Neurol. 2004, 55:410-417.
2. Achiron A., Feldman A., Mandel M., Gurevich M. Impaired expression of peripheral blood apoptotic-related gene transcripts in acute multiple sclerosis relapse. Ann. NY Acad. Sci. 2007, 1107:155-167.
3. Arthur A.T., Armati P.J., Bye C., Heard R.N., Stewart G.J., Pollard J.D., Booth D.R. Genes implicated in multiple sclerosis pathogenesis from consilience of genotyping and expression profiles in relapse and remission. BMC Med. Genet. 2008, 9:17.
4. Ascherio A., Munger K.L. Environmental risk factors for multiple sclerosis. Part I: the role of infection. Ann. Neurol. 2007, 61:288-299.
5. Ascherio A., Munger K.L. Environmental risk factors for multiple sclerosis. Part II: Noninfectious factors. Ann. Neurol. 2007, 61:504-513.
6. Babbe H., Roers A., Waisman A., Lassmann H., Goebels N., Hohlfeld R., Friese M., Schroder R., Deckert M., Schmidt S., Ravid R., Rajewsky K. Clonal expansions of CD8(+) T cells dominate the T cell infiltrate in active multiple sclerosis lesions as shown by micromanipulation and single cell polymerase chain reaction. J. Exp. Med. 2000, 192:393-404.
7. Baranzini S.E. The genetics of autoimmune diseases: a networked perspective. Curr. Opin. Immunol. 2009, 21:596-605.
8. Baranzini S.E., Elfstrom C., Chang S.Y., Butunoi C., Murray R., Higuchi R., Oksenberg J.R. Transcriptional analysis of multiple sclerosis brain lesions reveals a complex pattern of cytokine expression. J. Immunol. 2000, 165:6576-6582.
9. Baranzini S.E., Mudge J., van Velkinburgh J.C., Khankhanian P., Khrebtukova I., Miller N.A., Zhang L., Farmer A.D., Bell C.J., Kim R.W., May G.D., Woodward J.E., Caillier S.J., McElroy J.P., Gomez R., Pando M.J., Clendenen L.E., Ganusova E.E., Schilkey F.D., Ramaraj T., Khan O.A., Huntley J.J., Luo S., Kwok P.Y., Wu T.D., Schroth G.P., Oksenberg J.R., Hauser S.L., Kingsmore S.F. Genome, epigenome and RNA sequences of monozygotic twins discordant for multiple sclerosis. Nature 2010, 464:1351-1356.
10. Bennett J.L., Stuve O. Update on inflammation, neurodegeneration, and immunoregulation in multiple sclerosis: therapeutic implications. Clin. Neuropharmacol. 2009, 32:121-132.
11. Bjartmar C., Kidd G., Mork S., Rudick R., Trapp B.D. Neurological disability correlates with spinal cord axonal loss and reduce N-acetyl aspartate in chronic multiple sclerosis patients. Ann. Neurol. 2000, 48:893-901.
12. Bo L., Dawson T.M., Wesselingh S., Mork S., Choi S., Kong P.A., Hanley D., Trapp B.D. Induction of nitric oxide synthase in demyelinating regions of multiple sclerosis brains. Ann. Neurol. 1994, 36:778-786.
13. Bo L., Vedeler C.A., Nyland H., Trapp B.D., Mork S.J. Intracortical multiple sclerosis lesions are not associated with increased lymphocyte infiltration. Mult. Scler. 2003, 9:323-331.
14. Bo L., Vedeler C.A., Nyland H.I., Trapp B.D., Mork S.J. Subpial demyelination in the cerebral cortex of multiple sclerosis patients. J. Neuropathol. Exp. Neurol. 2003, 62:723-732.
15. Bomprezzi R., Ringner M., Kim S., Bittner M.L., Khan J., Chen Y., Elkahloun A., Yu A., Bielekova B., Meltzer P.S., Martin R., McFarland H.F., Trent J.M. Gene expression profile in multiple sclerosis patients and healthy controls: identifying pathways relevant to disease. Hum. Mol. Genet. 2003, 12:2191-2199.
16. Comabella M., Martin R. Genomics in multiple sclerosis - current state and future directions. J. Neuroimmunol. 2007, 187:1-8.
17. Crawford M.P., Yan S.X., Ortega S.B., Mehta R.S., Hewitt R.E., Price D.A., Stastny P., Douek D.C., Koup R.A., Racke M.K., Karandikar N.J. High prevalence of autoreactive, neuroantigen-specific CD8+ T cells in multiple sclerosis revealed by novel flow cytometric assay. Blood 2004, 103:4222-4231.
18. Dutta R., McDonough J., Yin X., Peterson J., Chang A., Torres T., Gudz T., Macklin W.B., Lewis D.A., Fox R.J., Rudick R., Mirnics K., Trapp B.D. Mitochondrial dysfunction as a cause of axonal degeneration in multiple sclerosis patients. Ann. Neurol. 2006, 59:478-489.
19. Dutta R., McDonough J., Chang A., Swamy L., Siu A., Kidd G.J., Rudick R., Mirnics K., Trapp B.D. Activation of the ciliary neurotrophic factor (CNTF) signalling pathway in cortical neurons of multiple sclerosis patients. Brain 2007, 130:2566-2576.
20. Eady J.J., Wortley G.M., Wormstone Y.M., Hughes J.C., Astley S.B., Foxall R.J., Doleman J.F., Elliott R.M. Variation in gene expression profiles of peripheral blood mononuclear cells from healthy volunteers. Physiol. Genomics 2005, 22:402-411.
21. Ebers G.C., Yee I.M., Sadovnick A.D., Duquette P. Conjugal multiple sclerosis: population-based prevalence and recurrence risks in offspring. Canadian Collaborative Study Group. Ann. Neurol. 2000, 48:927-931.
22. Evangelou N., Konz D., Esiri M.M., Smith S., Palace J., Matthews P.M. Size-selective neuronal changes in the anterior optic pathways suggest a differential susceptibility to injury in multiple sclerosis. Brain 2001, 124:1813-1820.
23. Ferguson B., Matyszak M.K., Esiri M.M., Perry V.H. Axonal damage in acute multiple sclerosis lesions. Brain 1997, 120:393-399.
24. Ganter P., Prince C., Esiri M.M. Spinal cord axonal loss in multiple sclerosis: a post-mortem study. Neuropathol. Appl. Neurobiol. 1999, 25:459-467.
25. Geschwind D.H., Konopka G. Neuroscience in the era of functional genomics and systems biology. Nature 2009, 461:908-915.
26. Giess R., Maurer M., Linker R., Gold R., Warmuth-Metz M., Toyka K.V., Sendtner M., Rieckmann P. Association of a null mutation in the CNTF gene with early onset of multiple sclerosis. Arch. Neurol. 2002, 59:407-409.
27. Giuliani F., Goodyer C.G., Antel J.P., Yong V.W. Vulnerability of human neurons to T cell-mediated cytotoxicity. J. Immunol. 2003, 171:368-379.
28. Goertsches R., Zettl U.K. MS therapy research applying genome-wide RNA profiling of peripheral blood. Int. MS J. 2007, 14:98-107.
29. Goertsches R.H., Hecker M., Koczan D., Serrano-Fernandez P., Moeller S., Thiesen H.J., Zettl U.K. Long-term genome-wide blood RNA expression profiles yield novel molecular response candidates for IFN-beta-1b treatment in relapsing remitting MS. Pharmacogenomics 2010, 11:147-161.
30. Graumann U., Reynolds R., Steck A.J., Schaeren-Wiemers N. Molecular changes in normal appearing white matter in multiple sclerosis are characteristic of neuroprotective mechanisms against hypoxic insult. Brain Pathol. 2003, 13:554-573.
31. Gregory S.G., Schmidt S., Seth P., Oksenberg J.R., Hart J., Prokop A., Caillier S.J., Ban M., Goris A., Barcellos L.F., Lincoln R., McCauley J.L., Sawcer S.J., Compston D.A., Dubois B., Hauser S.L., Garcia-Blanco M.A., Pericak-Vance M.A., Haines J.L. Interleukin 7 receptor alpha chain (IL7R) shows allelic and functional association with multiple sclerosis. Nat. Genet. 2007, 39:1083-1091.
32. Habek M., Borovecki F., Brinar V.V. Genomics in multiple sclerosis. Clin. Neurol. Neurosurg. 2010, 112:621-624.
33. Hafer-Macko C., Hsieh S.-T., Li C.Y., Ho T.W., Sheikh K.A. Acute motor axonal neuropathy: an antibody-mediated attack on axolemma. Ann. Neurol. 1996, 40:635-644.
34. Hafler D.A., Compston A., Sawcer S., Lander E.S., Daly M.J., De Jager P.L., de Bakker P.I., Gabriel S.B., Mirel D.B., Ivinson A.J., Pericak-Vance M.A., Gregory S.G., Rioux J.D., McCauley J.L., Haines J.L., Barcellos L.F., Cree B., Oksenberg J.R., Hauser S.L. Risk alleles for multiple sclerosis identified by a genomewide study. N. Engl. J. Med. 2007, 357:851-862.
35. Haines J.L., Terwedow H.A., Burgess K., Pericak-Vance M.A., Rimmler J.B., Martin E.R., Oksenberg J.R., Lincoln R., Zhang D.Y., Banatao D.R., Gatto N., Goodkin D.E., Hauser S.L. Linkage of the MHC to familial multiple sclerosis suggests genetic heterogeneity. The Multiple Sclerosis Genetics Group. Hum. Mol. Genet. 1998, 7:1229-1234.
36. Hardingham G.E., Fukunaga Y., Bading H. Extrasynaptic NMDARs oppose synaptic NMDARs by triggering CREB shut-off and cell death pathways. Nat. Neurosci. 2002, 5:405-414.
37. Hauser S.L., Oksenberg J.R. The neurobiology of multiple sclerosis: genes, inflammation, and neurodegeneration. Neuron 2006, 52:61-76.
38. Hecker M., Goertsches R.H., Fatum C., Koczan D., Thiesen H.J., Guthke R., Zettl U.K. Network analysis of transcriptional regulation in response to intramuscular interferon-beta-1a multiple sclerosis treatment. Pharmacogenomics J. 2010, Oct 19. [Epub ahead of print].
39. Ho T.W., McKhann G.M., Griffin J.W. Human autoimmune neuropathies. Annu. Rev. Neurosci. 1998, 21:187-226.
40. Hohlfeld R. Biotechnological agents for the immunotherapy of multiple sclerosis. Principles, problems and perspectives (invited review). Brain 1997, 120:865-916.
41. Huseby E.S., Liggitt D., Brabb T., Schnabel B., Ohlen C., Goverman J. A pathogenic role for myelin-specific CD8(+) T cells in a model for multiple sclerosis. J. Exp. Med. 2001, 194:669-676.
42. Khoury S.J., Guttmann C.R., Orav E.J., Kikinis R., Jolesz F.A., Weiner H.L. Changes in activated T cells in the blood correlate with disease activity in multiple sclerosis. Arch. Neurol. 2000, 57:1183-1189.
43. Kidd D., Barkhof F., McConnell R., Algra P.R., Allen I.V., Revesz T. Cortical lesions in multiple sclerosis. Brain 1999, 122:17-26.
44. Kinter J., Zeis T., Schaeren-Wiemers N. RNA profiling of MS brain tissues. Int. MS J. 2008, 15:51-58.
45. Kutzelnigg A., Lassmann H. Cortical lesions and brain atrophy in MS. J. Neurol. Sci. 2005, 233:55-59.
46. Lindberg R.L., De Groot C.J., Certa U., Ravid R., Hoffmann F., Kappos L., Leppert D. Multiple sclerosis as a generalized CNS disease-comparative microarray analysis of normal appearing white matter and lesions in secondary progressive MS. J. Neuroimmunol. 2004, 152:154-167.
47. Lipton S.A., Rosenberg P.A. Excitatory amino acids as a final common pathway for neurologic disorders. N. Engl. J. Med. 1994, 330:613-622.
48. Liu J.S., Zhao M.L., Brosnan C.F., Lee S.C. Expression of inducible nitric oxide synthase and nitrotyrosine in multiple sclerosis lesions. Am. J. Pathol. 2001, 158:2057-2066.
49. Lock C., Hermans G., Pedotti R., Brendolan A., Schadt E., Garren H., Langer-Gould A., Strober S., Cannella B., Allard J., Klonowski P., Austin A., Lad N., Kaminski N., Galli S.J., Oksenberg J.R., Raine C.S., Heller R., Steinman L. Gene-microarray analysis of multiple sclerosis lesions yields new targets validated in autoimmune encephalomyelitis. Nat. Med. 2002, 8:500-508.
50. Lovas G., Szilagyi N., Majtenyi K., Palkovits M., Komoly S. Axonal changes in chronic demyelinated cervical spinal cord plaques. Brain 2000, 123:308-317.
51. Medana I., Martinic M.A., Wekerle H., Neumann H. Transection of major histocompatibility complex class I-induced neurites by cytotoxic T lymphocytes. Am. J. Pathol. 2001, 159:809-815.
52. Munger K.L., Ascherio A. Risk factors in the development of multiple sclerosis. Expert. Rev. Clin. Immunol. 2007, 3:739-748.
53. Mycko M.P., Papoian R., Boschert U., Raine C.S., Selmaj K.W. cDNA microarray analysis in multiple sclerosis lesions: detection of genes associated with disease activity. Brain 2003, 126:1048-1057.
54. Mycko M.P., Papoian R., Boschert U., Raine C.S., Selmaj K.W. Microarray gene expression profiling of chronic active and inactive lesions in multiple sclerosis. Clin. Neurol. Neurosurg. 2004, 106:223-229.
55. Nave K.A., Trapp B.D. Axon-glial signaling and the glial support of axon function. Annu. Rev. Neurosci. 2008, 31:535-561.
56. Noseworthy J.H. Progress in determining the causes and treatment of multiple sclerosis. Nature 1999, 399:A40-A47.
57. Noseworthy J.H., Lucchinetti C., Rodriguez M., Weinshenker B.G. Multiple sclerosis. N. Engl. J. Med. 2000, 343:938-952.
58. Oksenberg J.R., Barcellos L.F. Multiple sclerosis genetics: leaving no stone unturned. Genes Immun. 2005, 6:375-387.
59. Oksenberg J.R., Baranzini S.E., Sawcer S., Hauser S.L. The genetics of multiple sclerosis: SNPs to pathways to pathogenesis. Nat. Rev. Genet. 2008, 9:516-526.
60. Peterson J.W., Bo L., Mork S., Chang A., Trapp B.D. Transected neurites, apoptotic neurons and reduced inflammation in cortical MS lesions. Ann. Neurol. 2001, 50:389-400.
61. Peterson J.W., Kidd G.J., Trapp B.D. Axonal Degeneration in Multiple Sclerosis: The Histopathological Evidence. Multiple Sclerosis as a Neuronal Disease 2005, 165-184. Elsevier, Ed S. Waxman.
62. Ramanathan M., Weinstock-Guttman B., Nguyen L.T., Badgett D., Miller C., Patrick K., Brownscheidle C., Jacobs L. In vivo gene expression revealed by cDNA arrays: the pattern in relapsing-remitting multiple sclerosis patients compared with normal subjects. J. Neuroimmunol. 2001, 116:213-219.
63. Rosati G. The prevalence of multiple sclerosis in the world: an update. Neurol. Sci. 2001, 22:117-139.
64. Satoh J., Nakanishi M., Koike F., Miyake S., Yamamoto T., Kawai M., Kikuchi S., Nomura K., Yokoyama K., Ota K., Kanda T., Fukazawa T., Yamamura T. Microarray analysis identifies an aberrant expression of apoptosis and DNA damage-regulatory genes in multiple sclerosis. Neurobiol. Dis. 2005, 18:537-550.
65. Skulina C., Schmidt S., Dornmair K., Babbe H., Roers A., Rajewsky K., Wekerle H., Hohlfeld R., Goebels N. Multiple sclerosis: brain-infiltrating CD8+ T cells persist as clonal expansions in the cerebrospinal fluid and blood. Proc. Natl. Acad. Sci. U.S.A. 2004, 101:2428-2433.
66. Smith K.J. Sodium channels and multiple sclerosis: roles in symptom production, damage and therapy. Brain Pathol. 2007, 17:230-242.
67. Sturzebecher S., Wandinger K.P., Rosenwald A., Sathyamoorthy M., Tzou A., Mattar P., Frank J.A., Staudt L., Martin R., McFarland H.F. Expression profiling identifies responder and non-responder phenotypes to interferon-beta in multiple sclerosis. Brain 2003, 126:1419-1429.
68. Tajouri L., Mellick A.S., Ashton K.J., Tannenberg A.E., Nagra R.M., Tourtellotte W.W., Griffiths L.R. Quantitative and qualitative changes in gene expression patterns characterize the activity of plaques in multiple sclerosis. Brain Res. Mol. Brain Res. 2003, 119:170-183.
69. Trapp B.D., Nave K.A. Multiple sclerosis: an immune or neurodegenerative disorder?. Annu. Rev. Neurosci. 2008, 31:247-269.
70. Trapp B.D., Stys P.K. Virtual hypoxia and chronic necrosis of demyelinated axons in multiple sclerosis. Lancet Neurol. 2009, 8:280-291.
71. Trapp B.D., Peterson J., Ransohoff R.M., Rudick R., Mork S., Bo L. Axonal transection in the lesions of multiple sclerosis. N. Engl. J. Med. 1998, 338:278-285.
72. Trapp B.D., Ransohoff R.M., Fisher E., Rudick R.A. Neurodegeneration in multiple sclerosis: relationship to neurological disability. Neuroscientist 1999, 5:48-57.
73. van der Valk P., De Groot C.J. Staging of multiple sclerosis (MS) lesions: pathology of the time frame of MS. Neuropathol. Appl. Neurobiol. 2000, 26:2-10.
74. Wandinger K.P., Sturzebecher C.S., Bielekova B., Detore G., Rosenwald A., Staudt L.M., McFarland H.F., Martin R. Complex immunomodulatory effects of interferon-beta in multiple sclerosis include the upregulation of T helper 1-associated marker genes. Ann. Neurol. 2001, 50:349-357.
75. Waxman S.G. Sodium channel blockers and axonal protection in neuroinflammatory disease. Brain 2005, 128:5-6.
76. Waxman S.G. Axonal conduction and injury in multiple sclerosis: the role of sodium channels. Nat. Rev. Neurosci. 2006, 7:932-941.
77. Weiner H.L. The challenge of multiple sclerosis: how do we cure a chronic heterogeneous disease. Ann. Neurol. 2009, 65:239-248.
78. Weinshenker B.G. Natural history of multiple sclerosis. Ann. Neurol. 1998, 36:S6-S11.
79. Weinshenker B.G., Bass B., Rice G.P., Noseworthy J., Carriere W., Baskerville J., Ebers G.C. The natural history of multiple sclerosis: a geographically based study. I. Clinical course and disability. Brain 1989, 112:133-146.
80. Whitney L.W., Becker K.G., Tresser N.J., Caballero-Ramos C.I., Munson P.J., Prabhu V.V., Trent J.M., McFarland H.F., Biddison W.E. Analysis of gene expression in mutiple sclerosis lesions using cDNA microarrays. Ann. Neurol. 1999, 46:425-428.
81. Whitney L.W., Ludwin S.K., McFarland H.F., Biddison W.E. Microarray analysis of gene expression in multiple sclerosis and EAE identifies 5-lipoxygenase as a component of inflammatory lesions. J. Neuroimmunol. 2001, 121:40-48.
82. Whitney A.R., Diehn M., Popper S.J., Alizadeh A.A., Boldrick J.C., Relman D.A., Brown P.O. Individuality and variation in gene expression patterns in human blood. Proc. Natl. Acad. Sci. U.S.A. 2003, 100:1896-1901.
83. Zeis T., Graumann U., Reynolds R., Schaeren-Wiemers N. Normal-appearing white matter in multiple sclerosis is in a subtle balance between inflammation and neuroprotection. Brain 2008, 131:288-303.
84. Zeis T., Probst A., Steck A.J., Stadelmann C., Bruck W., Schaeren-Wiemers N. Molecular changes in white matter adjacent to an active demyelinating lesion in early multiple sclerosis. Brain Pathol. 2009, 19:459-466.